Aurora Spine (ASG) Q2 2026 earnings summary

Executive summary

• Second quarter results were below expectations due to ongoing internal sales team restructuring and increased competition in the SI joint market.

• Strong performance in the spine segment, particularly with DEXA brand products and Apollo plates, offset some pain market declines.

• Strategic commercialization alliance with CornerLoc was initiated to expand SI joint product offerings and market reach.

• Management remains optimistic about future growth, citing a differentiated product portfolio, improved sales organization, and new product launches.

• Signed a new royalty agreement for the SiLO TFX implant, settling an arbitration dispute.

Financial highlights

• Q2 2026 revenue was $3.66 million, down 18.7% year-over-year from $4.5 million, mainly due to lower SI joint product sales.

• Gross profit margin was 60.1%, compared to 62.2% in Q2 2025.

• Operating expenses were $3.03 million, nearly flat year-over-year.

• EBITDAC was approximately -$501,809, down from $142,000 in the prior year quarter.

• Net loss was $834,763, compared to $199,000 in Q2 2025; EPS was -$0.01.

Outlook and guidance

• Management expects revenue improvement in the second half of the year as the restructured sales team gains traction.

• Strategic alliance with CornerLoc anticipated to broaden product offerings and drive long-term value.

• Focus remains on financial discipline, expense management, and improving accounts receivable collections.